Overview

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Status:
Not yet recruiting

Trial end date:
2023-11-19

Target enrollment:

Participant gender:

Summary

To find the highest tolerable dose of infigratinib that can be given in combination with bevacizumab and atezolizumab to patients with advanced/metastatic CCA with a FGFR2 mutation.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Helsinn Healthcare

Treatments:

Atezolizumab
Bevacizumab
Infigratinib